NASDAQ:NVUS Novus Therapeutics (NVUS) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.24▼$1.4150-Day Range$9.85▼$16.5052-Week Range$4.50▼$27.32Volume136,436 shsAverage Volume78,851 shsMarket Capitalization$1.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Novus Therapeutics (NASDAQ:NVUS) StockNovus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.Read More NVUS Stock News HeadlinesMay 11, 2023 | finance.yahoo.comNovo Holdings invests in US$105 million Series C Funding of Alentis TherapeuticsMarch 31, 2023 | benzinga.comProQR Therapeutics Stock (NASDAQ:PRQR), Analyst Ratings, Price Targets, PredictionsOctober 1, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.March 30, 2023 | finance.yahoo.comSales Revenue from CNS Therapeutics Market to Top US$ 142.1 Billion by 2026: Fact.MR AnalysisMarch 29, 2023 | proactiveinvestors.comChimeric Therapeutics welcomes “positive” feedback following pre-IND meeting with US FDA for Phase 1 CAR-T studyMarch 25, 2023 | usnews.comEast Career Technical AcademyMarch 25, 2023 | usnews.comLas Vegas Academy of the ArtsFebruary 22, 2023 | money.usnews.comPerspective Therapeutics IncOctober 1, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.February 12, 2023 | finance.yahoo.comOnychomycosis Therapeutics Market Size Worth US$ ~8,420.3 million , Globally, by 2030 at 6% CAGRMay 13, 2021 | markets.businessinsider.comNovus Therapeutics Inc Registered Shs hosts conference call for investorsJanuary 5, 2021 | apnews.comNovus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update ...January 4, 2021 | finance.yahoo.comNovus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and OutlookDecember 29, 2020 | finance.yahoo.comWe're Not Very Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn RateDecember 9, 2020 | finance.yahoo.comNovus Therapeutics Appoints June Lee, M.D., to Board of DirectorsDecember 2, 2020 | finance.yahoo.comIs Novus Therapeutics (NVUS) A Good Stock To Buy Now?November 16, 2020 | seekingalpha.comNovus Therapeutics EPS misses by $3.76November 10, 2020 | finance.yahoo.comNovus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16November 2, 2020 | finance.yahoo.comNovus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral SclerosisOctober 6, 2020 | nasdaq.comMoving Average Crossover Alert: Novus TherapeuticsOctober 2, 2020 | seekingalpha.comNovus Therapeutics announces 1-for-18 reverse stock splitSeptember 15, 2020 | finance.yahoo.comWhy Novus Therapeutics Is Trading Higher TodaySeptember 15, 2020 | finance.yahoo.comNovus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment ConferencesSeptember 15, 2020 | seekingalpha.comNovus Therapeutics rallies on Anelixis Therapeutics buySeptember 14, 2020 | markets.businessinsider.comAfter Hours Market: Marinus Pharma, Novus Therapeutics And NextEra Energy Gain; Nikola SlipsAugust 19, 2020 | markets.businessinsider.comNovus Therapeutics Inc Registered Shs - ProfileJune 2, 2020 | www.benzinga.comWhy Novus Therapeutics Is Trading Lower TodaySee More Headlines Receive NVUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NVUS Company Calendar Last Earnings11/16/2020Today10/01/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVUS CUSIPN/A CIK1404281 Webnovustherapeutics.com Phone949-238-8090FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($21.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-133.49% Return on Assets-30.52% Debt Debt-to-Equity RatioN/A Current Ratio18.78 Quick Ratio18.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.13 per share Price / Book0.10Miscellaneous Outstanding Shares1,436,000Free FloatN/AMarket Cap$1.97 million OptionableNot Optionable Beta2.07 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Jon S. Kuwahara CPA (Age 55)CPA, SVP of Fin. & Admin., Principal Financial Officer and Principal Accounting Officer Comp: $295.72kMr. Gregory J. Flesher (Age 50)Consultant Comp: $482.13kDr. David-Alexandre C. Gros M.D. (Age 48)CEO & Non Independent Director Dr. Steven N. Perrin Ph.D. (Age 55)Pres, Chief Scientific Officer & Non Independent Director Key CompetitorsAltamira TherapeuticsNASDAQ:CYTONeuBase TherapeuticsNASDAQ:NBSEInfinity PharmaceuticalsNASDAQ:INFIAyala PharmaceuticalsNASDAQ:ADXSNovaBay PharmaceuticalsNYSE:NBYView All Competitors NVUS Stock - Frequently Asked Questions How were Novus Therapeutics' earnings last quarter? Novus Therapeutics, Inc. (NASDAQ:NVUS) released its quarterly earnings results on Monday, November, 16th. The biopharmaceutical company reported ($5.51) EPS for the quarter, missing the consensus estimate of ($1.64) by $3.87. Read the conference call transcript. When did Novus Therapeutics' stock split? Shares of Novus Therapeutics reverse split on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Novus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Tonix Pharmaceuticals (TNXP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Novavax (NVAX), Geron (GERN), Inovio Pharmaceuticals (INO), Verastem (VSTM) and vTv Therapeutics (VTVT). What is Novus Therapeutics' stock symbol? Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS." What is Novus Therapeutics' stock price today? One share of NVUS stock can currently be purchased for approximately $1.37. How much money does Novus Therapeutics make? Novus Therapeutics (NASDAQ:NVUS) has a market capitalization of $1.97 million. The biopharmaceutical company earns $-16,010,000.00 in net income (profit) each year or ($21.58) on an earnings per share basis. How can I contact Novus Therapeutics? Novus Therapeutics' mailing address is 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612. The official website for the company is novustherapeutics.com. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at investors@novustherapeutics.com. This page (NASDAQ:NVUS) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.